ResMed Inc. (RMD) Stock Price: $198.60+2.10 (+1.07%)
At close: Jun 25, 2026, 4:00 PM ET
The closing share price for ResMed Inc. (RMD) stock was $198.60 for Thursday, June 25, 2026, up 1.07% on the day.
Longer view (total return, dividends reinvested): past 12 months -22.3% · 3-year avg -1.7%/yr · 5-year avg -3.2%/yr
RMD Price Chart
RMD Key Metrics
See All MetricsLAST CLOSE PRICE
$198.60
52-WEEK RANGE
$180.27 - $293.81
BETA
0.78
% FROM 52W HIGH
-32.41%
MARKET CAP
$28.81B
DIVIDEND YIELD
1.21%
PE RATIO
trailing TTM
19.21
PE RATIO (FWD)
next-FY estimate
16.22
P/B RATIO
4.50
DEBT / EQUITY
0.14
REVENUE TTM
$5.54B
NET INCOME TTM
$1.52B
NET PROFIT MARGIN TTM
27.44%
TTM TOTAL RETURN
-22.25%
3Y TOTAL RETURN
-1.68%
5Y TOTAL RETURN
-3.22%
RMD Revenue by Segment
How RMD’s revenue breaks down across its reported segments in the latest reported fiscal year.
By product / business (FY 2024)
- Sleep And Respiratory$4.10B87.5%
- Software As Service$584.13M12.5%
By geography (FY 2024)
- U [S]$2.98B63.6%
- Global$1.71B36.4%
RMD Earnings Preview
Next Earnings Date
Jul 30, 2026
34 days away
EPS Estimate
2.90
Revenue Est.
$1.47B
Last Quarter Results
EPS
$2.86
vs Estimate
$2.80
Revenue
$1.43B
vs Estimate
$1.42B
RMD Analyst Ratings
Consensus Rating
Based on 15 analysts
Average Price Target
$260.60
+31.2% upside
Low
$180.00
Current
$198.60
High
$325.00
RMD Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q3 2027 | $3.10 | $3.14 | $3.21 | 1 |
| Q4 2027 | $3.36 | $3.41 | $3.48 | 2 |
| Q1 2028 | $3.40 | $3.45 | $3.52 | 3 |
| Q2 2028 | $3.47 | $3.52 | $3.59 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $11.87 | $12.25 | $12.38 | 7 |
| FY 2028 | $12.53 | $13.44 | $13.86 | 4 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q3 2027 | $1.51B | $1.52B | $1.55B | 2 |
| Q4 2027 | $1.61B | $1.63B | $1.65B | 2 |
| Q1 2028 | $1.61B | $1.63B | $1.65B | 1 |
| Q2 2028 | $1.65B | $1.67B | $1.69B | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $6.06B | $6.08B | $6.10B | 12 |
| FY 2028 | $6.49B | $6.50B | $6.51B | 14 |
Source: FMP Analyst Consensus Estimates. Forward P/E uses the next-fiscal-year consensus EPS estimate (the same value shown in the Key Metrics strip).
Related Stocks
HealthcareRMD Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1RMD | $28.81B | $198.60 | +1.07% | -22.25% | -3.22% | +13.90% | — |
| 2BIIB | $29.82B | $201.96 | +1.19% | +58.69% | -10.31% | -1.25% | vs RMD |
| 3IQV | $31.12B | $186.43 | +0.44% | +17.48% | -5.34% | +11.40% | vs RMD |
| 4DXCM | $26.49B | $68.65 | -1.58% | -18.94% | -8.60% | +13.49% | vs RMD |
| 5VEEV | $25.68B | $158.08 | -2.03% | -43.46% | -12.74% | +16.51% | vs RMD |
| 6MDLN | $31.94B | $37.77 | +4.77% | N/A | N/A | N/A | vs RMD |
RMD Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About ResMed Inc.
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Michael J. Farrell